GSK Plc
GSK:LN
Latest Coverage
Overview
Company Profile
GSK has changed. In July 2022, we demerged our world-leading consumer healthcare business, Haleon. We are now a fully focused biopharma company.
We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.
Classification
Financials
News & Media
Latest Coverage
Corporate
Board of Directors
Sir Philip Hampton
Non-Executive Director
Sir Philip joined GSK as a Non-Executive Director on 1 January 2015 and became Non-Executive Chairman with effect from the conclusion of GSK\'s Annual General Meeting on 7 May 2015. Sir Philip is Senior Independent Director of Anglo American plc, Chairman of its Remuneration Committee and a member of its Audit Committee. Sir Philip has been Chairman of The Royal Bank of Scotland Group plc since February 2009. He was previously Chairman of J Sainsbury plc and Group Finance Director at Lloyds TSB Group, BT Group plc, BG Group plc, British Gas and British Steel plc. He is a former Executive Director of Lazards and a Non- Executive Director at RMC Group Plc and Belgacom SA. Sir Philip previously served as Chairman of UK Financial Investments Limited, which manages the UK Government’s shareholdings in banks.
Simon Dingemans
Chief Financial Officer
Simon became Chief Financial Officer in April 2011 after joining as Chief Financial Officer Designate in January 2011. He is a member of the Board and the Corporate Executive Team. Simon joined GSK from Goldman Sachs International where he was a Managing Director and Partner. He joined Goldman Sachs in 1995, becoming Head of UK Investment Banking and later becoming a leader of the European Mergers and Acquisitions business. As part of his role at GSK, Simon is responsible for Global Finance and Core Business Services comprising a number of the company’s key global functions including Finance and Real Estate. He worked with GSK for over a decade prior to joining the company and was closely involved in a number of GSK’s most important strategic projects during that time, including the establishment of ViiV Healthcare. After receiving a Masters degree in Geography from Oxford University in 1985, Simon joined S.G. Warburg Group, the investment banking firm which specialised in mergers and acquisitions, becoming one of its youngest directors in 1994. Simon is a member of the Corporate Development Council for the National Theatre and Chairman of the 100 Group.
Dr Moncef Slaoui
Chairman, Global Vaccines
Moncef is a member of the Board and the Corporate Executive Team. He was given overall responsibility for GSK\'s Oncology Business in 2010 and for GSK Vaccines in 2011. Prior to that he was Chairman, Research & Development, a position he had held since June 2006. In his previous position as Senior Vice President, Worldwide Business Development and External Alliances, he served on the R&D Executive Team and spearheaded recent changes in R&D to enhance drug discovery and accelerate product development. Before that, in GSK Vaccines, he engineered the development of a robust vaccines pipeline, including Rotarix, to prevent infantile gastroenteritis, and Cervarix, to prevent cervical cancer. Following a career in academia, he has demonstrated since joining the company in 1988 that he can create a strategic vision and then vigorously pursue it to develop new products that profoundly enhance healthcare. Moncef earned a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium, and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston. He was Professor of Immunology at the University of Mons, Belgium. Moncef has authored more than 100 scientific papers and presentations. Moncef is a member of the PhRMA and the Biotechnology Industry Organization boards in the USA, and a member of the Advisory Committee to the Director of National Institutes of Health. He is also an adviser to the Qatar Foundation, and a member of the Qatar Biomedical Research Institute Scientific Advisory Committee. Moncef is a Non-Executive Director of the International Aids Vaccine Initiative (IAVI). He was a member of the Board of the Agency for Science, Technology & Research (A*STAR) until January 2011. A citizen of Morocco, Belgium and the USA, he is fluent in English, French, and Arabic.
Sir Deryck Maughan
Senior Independent Non-Executive Director
Sir Deryck is a Non-Executive Director of BlackRock, Inc. as well as a Trustee of the British Museum and of New York University Langone Medical Center. Sir Deryck was previously a Senior Advisor and Partner of Kohlberg Kravis Roberts & Co, a Non-Executive Director of Thomson Reuters and served on the Board of Directors of the Lincoln Center. He was formerly Chairman and Chief Executive Officer of Citigroup International and of Salomon Brothers Inc. He served as Vice Chairman of the New York Stock Exchange from 1996 to 2000.
Professor Sir Roy Anderson
Independent Non-Executive Director
Sir Roy is the Professor of Infectious Disease Epidemiology in the Faculty of Medicine, Imperial College, London. He is a member of the International Advisory Board of Holdingham Group and is a Trustee of the National History Museum, London. He is also a member of the PTT Global Chemical Public Company Limited. He is a fellow of the Academy of Medical Sciences and the Royal Statistical Society. He is an Honorary Fellow of the Institute of Actuaries and a Foreign Associate Member of the National Academy of Medicine at the US National Academy of Sciences and the French Academy of Sciences. His former positions include Rector of Imperial College and Chief Scientific Adviser at the Ministry of Defence in the UK. Sir Roy has published over 450 scientific papers on the epidemiology, population biology, evolution and control of a wide variety of infectious disease agents, including HIV, BSE, vCJD, parasitic helminths and protozoa, and respiratory tract viral and bacterial infections. His principal research interests are epidemiology, biomathematics, demography, parasitology, immunology and health economics. He also has a keen interest in science policy and the public understanding of science. He received a knighthood in the Queen\'s Birthday Honours in June 2006.
Dr Stephanie Burns
Independent Non-Executive Director
Stephanie was formerly Chairman, President and Chief Executive Officer of Dow Corning Corporation, until her retirement on 31 December 2011. Stephanie was appointed a Non-Executive Director of Corning Inc. on 31 January 2012. She is a former Chairman of the American Chemistry Council and has also served on the boards of the Michigan Molecular Institute and the Society for Women’s Health Research. Stephanie joined Dow Corning in 1983 as a researcher working on water based and high temperature elastomers. She became director of Women\'s Health in 1994 and subsequently moved into corporate management becoming Science and Technology Director for Europe in 1997. She was first elected to Dow Corning\'s Board of Directors in December 2000, she was President and Chief Executive Officer from February 2003 until 2011, Chief Operating Officer from January 2004 until 2011 and was Chairman from January 2006 to December 2011. Stephanie holds a Ph.D. in organic chemistry, with an organosilicon specialty, from Iowa State University. She completed her post-doctoral studies at the Universite Montpellier, Sciences et Techniques du Languedoc, France.
Stacey Cartwright
Independent Non-Executive Director
Stacey is Chief Executive Officer of the Harvey Nichols Group of Companies. She served as Executive Vice President, Chief Financial Officer of Burberry Group plc until July 2013. Previously she held the role of Chief Financial Officer at Egg plc between 1999 and 2003, and from 1988 to 1999 she worked in various finance-related positions at Granada Group plc. In accordance with the UK Corporate Governance Code, the Board has determined that Stacey has recent and relevant financial experience. The Board has also agreed that she has the appropriate qualifications and background to be an audit committee financial expert as defined by the US Sarbanes-Oxley Act of 2002.
Lynn Elsenhans
Independent Non-Executive Director
Lynn was formerly Chair, President and Chief Executive Officer of Sunoco Inc. She joined Sunoco in 2008 as Chief Executive Officer and President, and was appointed Chair in 2009. She was President and Chief Executive Officer until March 2012, and was Chair until May 2012. Lynn served as a non executive director of International Paper Company between 2007 and 2012. Lynn was appointed as a Non-Executive Director of Baker Hughes Incorporated in May 2012. Lynn is a director of the Texas Medical Center, and a director of The First Tee of Greater Houston. She is also a Trustee of the United Way of Greater Houston and a Trustee of Rice University. Prior to joining Sunoco, she worked for Royal Dutch Shell, which she joined in 1980, and where she held a number of senior roles. From 2005 to 2008, she was Vice President, Global Manufacturing. She has a BA in Mathematical Sciences from Rice University, Houston and an MBA from Harvard University.
Judy Lewent
Independent Non-Executive Director
Judy is a Non-Executive Director of Thermo Fisher Scientific Inc. and Motorola Solutions Inc. She is also a Trustee and Chairperson of the Audit Committee of the Rockefeller Family Trust, a life member of the Massachusetts Institute of Technology Corporation and a member of the American Academy of Arts and Sciences. Judy served as Executive Vice President and Chief Financial Officer of Merck & Co., Inc. until September 2007. She also served as Chief Financial Officer starting in 1990 and held various other financial and management positions after joining Merck in 1980. She served on the Boards of Motorola Inc. from 1995 until May 2010 and Dell Inc. from 2001 to 2011 as well as previously serving on the Board of Quaker Oats Company. Judy has served as a Non-Executive Director on the Boards of Purdue Pharma Inc., Napp Pharmaceutical Holdings Limited and certain Mundipharma International Limited companies from 2009 to 2014. In accordance with the UK Corporate Governance Code, the Board has determined that Judy has recent and relevant financial experience. The Board has also agreed that she has the appropriate qualifications and background to be an audit committee financial expert as defined by the US Sarbanes-Oxley Act of 2002.
Dr Daniel Podolsky
Independent Non-Executive Director
Daniel is President of the University of Texas Southwestern Medical Center in Dallas and holds the Philip O’Bryan Montgomery, Jr M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science. Daniel is a member of the National Academy of Medicine at the US National Academy of Sciences, the Council of Teaching Hospitals of the Association of Academic Medical Centers, and sits on the Board of the Southwestern Medical Foundation. He is also a Director of Antibe Therapeutics, Inc, and a member of the National Academies of Sciences Board on Army Science and Technology. Previously, he served as Co-Chairman of the Board and Scientific Co-Founder of the GI Company, Inc, served as the Chief Academic Officer of Partners HealthCare System and was formerly Mallinckrodt Professor of Medicine and Chief of Gastroenterology at Massachusetts General Hospital and Harvard Medical School. Daniel is a world-renowned researcher who has advanced knowledge of underlying mechanisms of disease and new therapies for gastrointestinal disorders. He is also an international authority on trefoil proteins and innate immunity. Daniel has published and patented widely in his field, He is past editor-in-chief of Gastroenterology, the leading journal in the field, and is immediate Past President of the
Urs Rohner
Independent Non-Executive Director
Mr Rohner is currently Chairman of Credit Suisse Group AG, one of the world’s leading financial services companies. Mr Rohner was appointed Chairman of Credit Suisse in 2011 following a number of senior positions at the company including General Counsel and Chief Operating Officer. Before joining Credit Suisse in 2004, he was Chief Executive Officer and Chairman for four years at ProSiebenSat.1 Group, one of the largest independent media corporations in Europe. This followed a number of years in private practice at major law firms in Switzerland and the USA. Urs has a legal background having been admitted to the bars of the canton of Zurich in 1986 and the state of New York in 1990.
Hans Wijers
Independent Non-Executive Director
Hans is a Non-Executive Director and Chairman of Heineken NV, Deputy Chairman and Non-Executive Director of Royal Dutch Shell. He is also Chairman of the supervisory board of AFC Ajax and Member of the supervisory board of HAL Holding N.V. Hans has a broad range of business, economic and political experience, having served as Chief Executive Director and Chairman at Akzo Nobel NV from 2002 to 2012. He has had a long and distinguished career in academia, public service and strategy consulting, and he served as senior vice president of the Boston Consulting Group from 1998 to 2002.
Sir Andrew Witty
Chief Executive Officer
Andrew became Chief Executive Officer of GlaxoSmithKline plc on 21 May 2008. He is a member of the Board and Corporate Executive Team. Andrew joined GSK in 1985. He has worked in the UK, South Africa, the USA and Singapore in various senior roles. In 2003, he was appointed President of GSK Europe and joined GSK’s Corporate Executive Team. In 2003 he was awarded the Public Service Medal by the Government of Singapore and in August 2012 was also awarded the Public Service Star. In the 2012 New Year Honours list, he was awarded a Knighthood for services to the economy and to the UK pharmaceutical industry. Andrew served as the Lead Non-Executive Board Member for the Department for Business, Innovation and Skills to December 2013. He was also President of the European Federation of Pharmaceutical Industries and Associations until June 2013. Andrew is a Member of the UK Prime Minister’s Business Advisory Group and Member of the Global Health Innovation Advisory Board, Imperial College London. He is Chancellor of the University of Nottingham and was appointed to the UK Business Ambassador Group in January 2014. Andrew has a Joint Honours BA in Economics from the University of Nottingham.